- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 14
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of August 14, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 14.
Number 5: Biocon has withdrawn its filings for 2 biosimilars in Europe ahead of a re-inspection of its Bangalore manufacturing facility. The move sparked new questions as to whether the company’s trastuzumab will be cleared by the FDA next month.
Number 4: Dr Marcus Snow, of the University of Nebraska Medical Center, joined The Center for Biosimilars® to discuss the use of biosimilar treatments in children.
Number 3: With drug price reform efforts apparently stalled at the federal level, states are leading the fight against rising drug costs.
Number 2: A recent budget impact analysis shows that discounts for biosimilar infliximab may need to be deeper than previously believed in order to encourage uptake.
And Number 1: Rebates provided to PBMs by reference product sponsors may pose a threat to biosimilar uptake, and could force patients to pay high out-of-pocket costs.
Finally, last week, our newsletter asked you to share your thoughts on switching studies, and whether such studies should use a US-licensed reference product, an EU-licensed product, or a product approved by any global healthcare agency. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To read these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
